Dallas, TX -- (SBWIRE) -- 12/02/2014 -- The report "Intracerebral Hemorrhage Pipeline Review H2 2014" provides comprehensive information on the treatment development for Intracerebral Reduce blood vessels, complete with comparative research at various levels, therapeutics assessment by drugs focus on, process of action (MoA), direction of management (RoA) and substance type, along with latest up-dates, and provided news and media reports. It also views key players involved in the treatment development for Intracerebral Reduce blood vessels and special features on late-stage and ceased projects.

Complete Report is Available
http://www.rnrmarketresearch.com/intracerebral-hemorrhage-pipeline-review-h2-2014-market-report.html

Intracranial may occur within brain parenchyma or the surrounding meningeal spaces. The cause is usually high blood pressure. Companies discussed in this Intracerebral Hemorrhage Pipeline Review H2 2014 report include ActiveSite Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., MediPost Co., Ltd. & Pfizer Inc.

Drugs profile discussed in this Intracerebral Hemorrhage Pipeline Review H2 2014 report include alteplase, ASP-440, PF-05230907, Pneumostem, Stem Cell Therapy for Cerebral Hemorrhage.

Order a Purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=244999

The report "Mixed Dyslipidemia Pipeline Review H2 2014" provides comprehensive information on the treatment development for Mixed Dyslipidemia, complete with comparative research at various levels, therapeutics assessment by drugs concentrate on, process of action (MoA), direction of control (RoA) and substance type, along with latest up-dates, and provided information and media reports. It also views key players engaged in the treatment development for Mixed Dyslipidemia and special functions on late-stage and ceased projects.

Complete Report is Available
http://www.rnrmarketresearch.com/mixed-dyslipidemia-pipeline-review-h2-2014-market-report.html

Mixed Dyslipidemia is abnormal levels of fats and or cholesterol in the blood. Companies discussed in this Mixed Dyslipidemia Pipeline Review H2 2014 report include Amgen Inc., CymaBay Therapeutics, Inc., Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc.

Drugs profile discussed in this Mixed Dyslipidemia Pipeline Review H2 2014 report include bococizumab, evolocumab, INSUPR-001, MAT-9001, MBX-8025, TAP-311.

Order a Purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=245003

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Major points in Table of Content
List of Tables
Number of Products under Development for Mixed Dyslipidemia, H2 2014
Number of Products under Development for Mixed Dyslipidemia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Mixed Dyslipidemia - Pipeline by Amgen Inc., H2 2014
Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2014
Mixed Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2014
Mixed Dyslipidemia - Pipeline by Novartis AG, H2 2014
Mixed Dyslipidemia - Pipeline by Pfizer Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2014
Mixed Dyslipidemia - Dormant Projects, H2 2014
Mixed Dyslipidemia - Discontinued Products, H2 2014

List of Figures
Number of Products under Development for Mixed Dyslipidemia, H2 2014
Number of Products under Development for Mixed Dyslipidemia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

Explore more reports on Therapeutics industry
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics